产金属β-内酰胺酶细菌的治疗药物研究进展
Research progress on drugs in treatment of metal-producing β-lactamase bacteria
符梦瑜 1郑裕彤 1周伟全 1陈秀会 1叶卫军1
作者信息
- 1. 东莞市第八人民医院(东莞市儿童医院) 药学部 东莞市精准药学与药物基础研究重点实验室,广东 东莞 523000
- 折叠
摘要
金属β-内酰胺酶属于B类β-内酰胺酶,可广泛水解除单环外的其余β-内酰胺类抗生素.产金属β-内酰胺酶的菌株常常表现为多重耐药,增加了临床抗感染治疗的难度.产金属 β-内酰胺酶细菌的治疗药物主要包括基于氨曲南的药物联合治疗、头孢地尔、新型β-内酰胺酶抑制剂联合治疗和基于传统抗生素类结构研发的新型抗生素.基于此,概述了产金属β-内酰胺酶细菌的治疗药物的研究进展,以期为产金属β-内酰胺酶细菌感染的临床治疗提供参考.
Abstract
Metal β-lactamases belong to class B β-lactamases,and can extensively hydrolyze all β-lactam antibiotics except for monocyclic antibiotics.Metal-producing β-lactamase strains often exhibit multiple drug resistance,increasing the difficulty of clinical anti-infection treatment.Drugs in treatment of metal-producing β-lactamase bacteria mainly include combination drug based on amtreonam,cefiderocol,novel drugs β-lactam combination with β-lactamase inhibitors,and newly developed antibiotics based on traditional antibiotic structures.Therefore,this article summarizes research progress on drugs in treatment of metal-producing β-lactamase bacteria,to provide references for clinical treatment of bacterial infections caused by metal-producing β-lactamase bacteria.
关键词
产金属β-内酰胺酶/多重耐药/氨曲南/头孢地尔/β-内酰胺酶抑制剂/新型抗生素Key words
metal-producing β-lactamase/multiple drug resistance/amtreonam/cefiderocol/β-lactamase inhibitor/new antibiotic引用本文复制引用
基金项目
东莞市社会发展科技面上项目(20221800900152)
出版年
2024
NETL
NSTL
万方数据